Beyond weight loss, retatrutide has shown promise in improving insulin resistance, reducing visceral fat and potentially increasing overall energy expenditure
It helps with blood sugar and weight loss too
Gradual titration was used to reduce gastrointestinal adverse effects common to incretin therapies
We're no longer talking about "weight loss drugs." We're talking about treatments that simultaneously address visceral fat, liver fat, glycemic control, cardiovascular risk, sleep apnea, and joint disease
There is no clinical data on this combination, and it is generally not recommended because the GLP-1 receptor activation from multiple compounds would overlap, potentially increasing gastrointestinal side effects without proportional benefit
For those unfamiliar, GLP-1 receptor agonists are prescription medications that mimic the GLP-1 hormone that stimulates insulin release, suppresses appetite and slows digestion